BFRI (Biofrontera) Total Operating Expense: $44.12 Mil (TTM As of Mar. 2026)


BFRI Biofrontera Inc BFRI
44 GF Score
Price $1.02
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera Total Operating Expense?

Biofrontera BFRI +4.08% 44 Total Operating Expense is $44.12 Mil as of Mar. 2026. GuruFocus rates BFRI with a GF Score™ of 44/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Biofrontera's Total Operating Expense for the three months ended in Mar. 2026 was $11.90 Mil. Biofrontera's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $44.12 Mil.

Biofrontera Total Operating Expense Related Terms

Biofrontera Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biofrontera's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera Total Operating Expense Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 37.21 35.87 39.20 35.92 42.09

Biofrontera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.87 11.47 11.22 9.53 11.90
BFRI
44GF Score
Biofrontera Inc BFRI
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $44.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $44.12 Mil mean?
Biofrontera (BFRI) has a Total Operating Expense of $44.12 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biofrontera and its competitors.
Is Biofrontera's Total Operating Expense too high?
Biofrontera's current Total Operating Expense is $44.12 Mil. Overall, Biofrontera has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Total Operating Expense compare to BIOE and APUS?
Biofrontera's Total Operating Expense of $44.12 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biofrontera and its competitors. Biofrontera's current Total Operating Expense is $44.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.02 — trading 88.9% above its estimated fair value. The current Total Operating Expense is $44.12 Mil. Biofrontera's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biofrontera (BFRI), the current Total Operating Expense is $44.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $1.02 is trading 88.9% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Total Operating Expense: $44.12 Mil
  • GF Value™: $0.54 vs. price of $1.02 (88.9% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price
$0.54
GF Value